drugset
drugset / Trial / NCT01181232

A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients

NCT01181232 ↗

Phase 4 Completed 132 enrolled Astellas Pharma Inc Astellas Pharma Taiwan, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of zolpidem MR (modified release) compared to zolpidem IR (immediate release) in patients with primary insomnia.

Timeline

Start
2009-10
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolpidem Small molecule — Oral

Indications

insomnia sleep disorder, initiating and maintaining sleep